Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Weinstock

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Nature Genetics|April 22, 2014
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylationAndrew A Lane, Bjoern Chapuy, Charles Y Lin, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual diseasePeter S Winter, Michelle L Ramseier, Andrew W Navia, et al.
Disaster Medicine and Public Health Preparedness|June 18, 2019
Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE)C Norman Coleman, Judith L Bader, John F Koerner, et al.
Nature Medicine|November 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Cell Reports|April 25, 2020
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular LymphomaDeepak Bararia, Johannes A Hildebrand, Sebastian Stolz, et al.
Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Nature Genetics|April 22, 2014
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylationAndrew A Lane, Bjoern Chapuy, Charles Y Lin, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual diseasePeter S Winter, Michelle L Ramseier, Andrew W Navia, et al.
Disaster Medicine and Public Health Preparedness|June 18, 2019
Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE)C Norman Coleman, Judith L Bader, John F Koerner, et al.
Nature Medicine|November 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Cell Reports|April 25, 2020
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular LymphomaDeepak Bararia, Johannes A Hildebrand, Sebastian Stolz, et al.
Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Pageof 18